The phenomenon of acquired resistance to chemotherapeutic agents is a long-standing
conundrum in cancer treatment. To help delineate drug resistance mechanisms and pave …

To study the mechanism of acquired resistance to bortezomib, a new antitumor drug that is
the first therapeutic proteasome inhibitor, we established a series of bortezomib-resistant T …

To study the mechanism of acquired resistance to bortezomib, a new antitumor drug that is
the first therapeutic proteasome inhibitor, we established a series of bortezomib-resistant T …

Bortezomib (Velcade™) is a reversible proteasome inhibitor that is approved for the
treatment of multiple myeloma (MM). Despite its demonstrated clinical success, some …

The proteasome inhibitor, bortezomib, a boronic dipeptide which reversibly inhibit the
chymotrypsin-like activity at the β5-subunit of proteasome (PSMB5), has marked efficacy …

Bortezomib (BTZ), a proteasome inhibitor, is the first proteasome inhibitor to be used in
clinical practice. Here we investigated the mechanisms underlying acquired bortezomib …

The ubiquitin–proteasome pathway is an important protein quality control system involved in
intracellular homeostasis. To achieve intracellular homeostasis, proteins that are misfolded …

Bortezomib (aka as velcade or PS-341) is used in the clinic to treat multiple myeloma (MM)
and mantle cell lymphoma (Dou and Zonder, 2014). In addition to the pharmacokinetic …

The proteasome is an intracellular enzyme complex that degrades ubiquitin-tagged proteins
and thereby regulates protein levels within the cell. Given this important role in maintaining …

PSMB5 mutations and upregulation of the β5 subunit of the proteasome represent key
determinants of acquired resistance to the proteasome inhibitor bortezomib (BTZ) in …